CN100478025C - Cyclosporia A microemulsion for eye and its preparation method - Google Patents
Cyclosporia A microemulsion for eye and its preparation method Download PDFInfo
- Publication number
- CN100478025C CN100478025C CNB2005100246445A CN200510024644A CN100478025C CN 100478025 C CN100478025 C CN 100478025C CN B2005100246445 A CNB2005100246445 A CN B2005100246445A CN 200510024644 A CN200510024644 A CN 200510024644A CN 100478025 C CN100478025 C CN 100478025C
- Authority
- CN
- China
- Prior art keywords
- cyclosporin
- eyes
- microemulsion formulation
- purified water
- microemulsion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A microemulsion of cyclosporin A used for eyes is prepared from cyclosporin A, oil phase, emulsifier (polyoxyvinyl castor oil or hydrogenated polyoxyvinyl castor oil), viscosity increaser, glycerine, bacterial inhibitor, sodium hydroxide and purified water.
Description
Technical field
The present invention relates to microemulsion formulation, be specifically related to a kind of ocular microemulsion preparation that contains cyclosporin A, the invention still further relates to the preparation method of this ocular microemulsion preparation.
Background technology
Cyclosporin A is a kind of nonpolar cyclic oligopeptide medicine with immunosuppressive activity, is mainly used in the immunologic rejection treatment that autoimmune disease and organ suppress.Ciclosporin can suppress immunologically competent cell, especially T lymphocyte by selectivity.And the release of the generation of lymphokine, IFN-, interleukin-22, T cell growth factor all is suppressed, therefore cyclosporin A can be used as a kind of local immunity regulator and is applied to eye, suppress the lymphocytic activity of T in the lachrymal gland, thereby strengthen or recovery lacrimal gland function (PCT patent application WO8901772).In addition, cyclosporin A is made ophthalmic preparation, can avoid the toxic and side effects comparatively serious that causes after its whole body administration human liver, kidney, nervous system.
Cyclosporin A dissolves in organic solvent, and is water-soluble hardly.Commercially available cyclosporin A preparation mostly is and contains alcoholic acid oil-soluble preparations at present.As oral formulations is the self-emulsifying microemulsion system that contains ethanol, emulsifying agent and oil.In order to improve the dissolubility of cyclosporin A in water, need in the ejection preparation to add emulsifying agent with solubilising, but this anaphylaxis can cause intravenous administration the time.Change of configuration takes place in cyclosporin A easily, often presents physical instability in oily preparation, separates out (U.S. Pat P5474979) as crystallization, thereby has a strong impact on the stable and curative effect of its quality of the pharmaceutical preparations.
The cyclosporin A oil-including formulation is not suitable for the clinical treatment that directly applies to ocular disease, because if the oil-including formulation of cyclosporin A is directly splashed into eye, meeting produces stimulation because of the preparation oil-containing to eye and causes the thickness sense of discomfort of eye, may increase the weight of some diseases of eye surface thus.
The cyclosporin A preparation that is used for dosing eyes of report is mainly Emulsion at present, and all there is certain problem in wherein common Emulsion in long-term placement and follow-up sterilization process, and this brings certain difficulty to suitability for industrialized production and clinical safety application.And microemulsion is to have excellent absorbability, and has overcome above-mentioned defective, so microemulsion is a direction of development cyclosporin A ophthalmic preparation.Emulsifying agent is one an essential composition in the Emulsion prescription, because most of emulsifying agents have very strong zest to eye, therefore selecting suitable emulsifying agent is one of key of developing emulsion of cyclosporin A for eyes.U.S. Pat P1152876 has reported a kind of ciclosporin ophthalmic emulsion, and this Emulsion adopts its Tween 80 as emulsifying agent.Existing being reported in clinically of sandimmun neoral (the oral self-micro emulsion formulation of ciclosporin) can be carried out dosing eyes after forming microemulsion after the suitable dilution, but owing to wherein contain certain density ethanol, and emulsifier proportion is very high, eyes there are certain stimulation and toxic and side effects (Knagenhjelm SK etc., Acta Ophthalmol Scand., 1999, Apr; 77 (2): 200-203).F.Lallemand etc. also report the prescription and the preparation technology of ciclosporin microemulsion formulation, but the eye safety evaluatio of being correlated with as yet.(EuropeanJournal?of?Pharmaceutics?and?Biopharmaceutics，2003，56：307-318)。
Summary of the invention
The purpose of this invention is to provide a kind of cyclosporin A for eyes microemulsion formulation, this ocular microemulsion preparation is applicable to the eye sensitive part, has comfort level height, non-irritating characteristics, can be absorbed by selectivity in lachrymal gland.
Another object of the present invention is to provide the preparation method of this ocular microemulsion preparation.
Cyclosporin A for eyes of the present invention is prepared by ciclosporin A, oil phase, emulsifying agent, viscosifier, glycerol, antibacterial, sodium hydroxide, purified water with microemulsion formulation, form through shearing-high pressure homogenize prepared, be translucent and light blue opalescence is arranged, pH value is 6.2-8, the emulsion droplet mean diameter is less than 100nm, and 90% particle diameter accumulated value is not more than 200nm.Cyclosporin A for eyes of the present invention is to adopt safety, non-irritating non-ionic surfactant polyoxyethylene Oleum Ricini (Cremophor EL) or polyoxyethylene hydrogenated Oleum Ricini as emulsifying agent with the characteristics of microemulsion formulation, and main adjuvant also comprises glycerol and Oleum Ricini or three sad caprins.
Cyclosporin A for eyes of the present invention is with (in the content in the 1000ml microemulsion formulation) composed as follows of microemulsion formulation:
Ciclosporin A 0.005g-5g
Oil phase 0.06g-30g
Emulsifying agent 0.3g-50g
Viscosifier 0.0g-1.0g
Glycerol 26g
Antibacterial 0.0g-0.5g
Sodium hydroxide is an amount of
Purified water is an amount of
Solvent is a purified water in the above-mentioned prescription; Oil phase adopts Oleum Ricini or three sad caprins; Emulsifying agent adopts polyoxyethylene castor oil or polyoxyethylene hydrogenated Oleum Ricini; Viscosifier can adopt carbomer, hydroxypropyl methylcellulose or polyvidone etc.; Antibacterial can adopt benzalkonium chloride or benzalkonium bromide; Wherein the preferred weight ratio of cyclosporin A and oil phase is 0.02～0.12; The preferred weight ratio of oil phase and emulsifying agent is 0.5～2.
Cyclosporin A for eyes of the present invention is to adopt shearing-high pressure homogenize technology with the characteristics of the preparation method of microemulsion formulation, and operating procedure is with oil phase, emulsifying agent, glycerol mix homogeneously under 60 ℃ of conditions, then cyclosporin A is dissolved in the mixture.Add an amount of purified water, emulsification pretreatment obtains colostrum, and then uses the high pressure homogenizer homogenizing, regulates viscosity to 2.6-3.5cp with tackifier water solution subsequently; The reuse sodium hydroxide solution is regulated pH to 6.2-8; Add the recipe quantity antibacterial at last, mend to capacity with purified water, the product that makes is with the filtering with microporous membrane of 0.45 μ m, promptly.
The critical process of said method is with high pressure homogenizer the colostrum that emulsification pretreatment obtains to be carried out homogenizing, and the homogenization pressure of high pressure homogenize should be more than or equal to 100, and 000kPa, homogenizing time are 1-20 hour.With the microemulsion formulation of shearing-high pressure homogenize prepared, the emulsion droplet mean diameter significantly is lower than the 150nm Emulsion particle diameter that common shearing technology makes less than 100nm, forms microemulsion system.
Below by experiment eye safety and the stability of cyclosporin A for eyes of the present invention with microemulsion formulation is described:
One, cyclosporin A for eyes of the present invention is with the irritation test of microemulsion formulation to the rabbit eye
1, test material and condition:
Trial drug: according to the cyclosporin A for eyes microemulsion formulation of embodiment 1 described prescription and method preparation, the concentration of this microemulsion formulation is 0.05% (m/v), and each dosage is 100 μ l;
Experimental animal: 4 of cleaning level New Zealand white rabbit, male and female half and half, body weight 2-3 kilogram (available from the extraordinary animals and plants of peace breeding farm, Shanghai);
Animal feeding environment: feed for rabbit source: Shanghai Shi Lin Science and Technology Ltd.
Room temperature: 20 ℃
Humidity: 30%-70%
Illumination: artificial light rays, 12 hours daylight, 12 hours dark
The Laboratory Animal Facility quality certification number: SYXK (Shanghai) 2003-0029
2, test method:
Draw back tame lagophthalmos conjunctival sac gently, the 0.1ml trial drug is splashed in the eye conjunctival sac of right side, the left side gives normal saline in contrast.Made eyes after the administration passive closed 5～10 seconds (action is light), medicinal liquid is had fully with the part contact.Be administered twice every day, one week of successive administration.The degree of impairment of eye in 6,24,48,72,96,120,144,168 hours after the record administration is with Draize eye irritant test scoring expression (according to the 208th page of " new drug (Western medicine) clinical research guideline compilation (pharmacology pharmacology's toxicology) " eye irritant test).Check corneal injury with fluorescein sodium during observation, change with slit lamp examination corneal transparence and iris texture.
3, result of the test:
Each test period is put tame lagophthalmos stimulates score value to see Table 1.
Each test period of table 1 is put tame lagophthalmos stimulates score value
According to Draize eye irritation evaluation criterion, 0-3 is divided into nonirritant, and as can be seen from Table 1, stimulating a score value at the eye of each test period point is 0～0.5, so cyclosporin A for eyes of the present invention is put equal nonirritant to the rabbit eyes in each test period with microemulsion formulation.Through slit lamp and fluorescein sodium inspection, cornea and iris are all normal simultaneously.Because this pilot system is than human eye irritant reaction sensitivity, so the irritant reaction feminine gender can be determined the human eye nonirritant.
Investigate cyclosporin A for eyes of the present invention by the test of ophthalmic pharmacokinetics in addition and confirm that with the distribution results of microemulsion formulation in the lagophthalmos tissue cyclosporin in this dosing eyes system can be used for the treatment of xerophthalmia.
Two, the cyclosporin A for eyes of the present invention stability test of microemulsion formulation
(1), accelerated test
Cyclosporin A for eyes according to embodiment 1 described prescription and method preparation is packed under (the LDPE bottle is packed) condition in the plan listing with microemulsion formulation, in temperature is 40 ℃ ± 2 ℃, relative humidity is to place 6 months in 20 ± 5% the environment, and timing sampling is checked indexs such as outward appearance, medicament contg, related substance, pH value and emulsion droplet particle diameter.Its result of the test sees Table 2:
Table 2 commercially available back sample accelerated test result
As can be seen from Table 2, intending under the listing terms of packing, under the accelerated test condition of 40 ℃ of relative humiditys 20%, temperature, placed 6 months, cyclosporin A for eyes of the present invention does not all take place obviously to change steady quality with every indexs such as appearance character, medicament contg, related substance, pH value and particle diameter of microemulsion formulation.
(2), the room temperature test that keeps sample
Cyclosporin A for eyes according to embodiment 1 described prescription and method preparation is packed under (the LDPE bottle is packed) condition in the plan listing with microemulsion formulation, in temperature is 25 ℃ ± 2 ℃, relative humidity is to place 6 months in 60 ± 10% the environment, and timing sampling is checked indexs such as outward appearance, medicament contg, related substance, pH value and emulsion droplet particle diameter.Its result of the test sees Table 3:
The table 3 commercially available back sample room temperature long-term test results that keeps sample
As can be seen from Table 3, intending under the listing terms of packing, under the approaching actual storage requirement of 25 ℃ of relative humiditys 60%, temperature, placed 6 months, cyclosporin A for eyes of the present invention does not all take place obviously to change steady quality with every indexs such as appearance character, medicament contg, related substance, pH value and particle diameter of microemulsion formulation.
Beneficial effect
1, cyclosporin A for eyes of the present invention is an emulsifying agent with microemulsion formulation employing safety, non-irritating non-ionic surfactant polyoxyethylene Oleum Ricini or agent polyoxyethylene hydrogenated Oleum Ricini, be fit to be applied to the eye sensitive part, have comfort level height, non-irritating advantage.
2, the present invention adopts the cyclosporin A for eyes that shearing-the high pressure homogenize prepared obtains to use microemulsion formulation emulsion droplet mean diameter less than 100nm, significantly be lower than the 150nm Emulsion particle diameter that common shearing technology makes, form microemulsion system, to eye nonirritant and toxic and side effects and have good stability.
The specific embodiment
The present invention is further elaborated below in conjunction with specific embodiment, but do not limit the present invention.Cyclosporin A is available from Fujian KeRui pharmacy Co., Ltd among the following embodiment, and the emulsion droplet mean diameter is measured with the particle size analyzer of dynamic light scattering principle.
Embodiment 1
Prescription is formed: ciclosporin A 0.5g
Oleum Ricini 6g
Polyoxyethylene castor oil 15g
Carbomer (Pemulen) 0.05g
Glycerol 26g
Sodium hydroxide is an amount of
Benzalkonium chloride 0.05g
Purified water is an amount of
Make 1000ml
Preparation method: take by weighing each component according to the prescription composition,, then cyclosporin A is dissolved in the mixture with Oleum Ricini, polyoxyethylene castor oil and glycerol mix homogeneously under 60 ℃ of conditions.Add an amount of purified water, emulsification pretreatment obtains colostrum, and then (pressure was about 140,000kPa), regulates viscosity to 2.6-3.5cp with the carbomer aqueous solution subsequently with high pressure homogenizer homogenizing 4 hours; The reuse sodium hydroxide solution is adjusted to pH6.2-8; Subsequently, add the recipe quantity benzalkonium chloride, mend to 1000ml with purified water, the product that makes is with the filtering with microporous membrane of 0.45 μ m.The mean diameter of prepared after measured microemulsion emulsion droplet is 60nm, with prepared microemulsion formulation with the centrifugal 15min of 4000rpm speed after, outward appearance still is light blue translucent Emulsion, and is not stratified.
Comparative example 1
Prescription is formed: ciclosporin A 0.5g
Oleum Ricini 6g
Tween 80 15g
Carbomer (Pemulen) 0.05g
Glycerol 26g
Sodium hydroxide is an amount of
Benzalkonium chloride 0.05g
Purified water is an amount of
Make 1000ml
Preparation method: take by weighing each component according to the prescription composition,, then cyclosporin A is dissolved in the mixture with Oleum Ricini, Tween 80 and glycerol mix homogeneously under 60 ℃ of conditions.Add an amount of purified water, emulsification pretreatment obtains colostrum, regulates viscosity to 2.6-3.5cp with the carbomer aqueous solution subsequently; The reuse sodium hydroxide solution is adjusted to pH6.2-8; Subsequently, add the recipe quantity benzalkonium chloride, mend to 1000ml with purified water, the product that makes is with the filtering with microporous membrane of 0.45 μ m.With prepared microemulsion formulation with the centrifugal 15min of 4000rpm speed after, obvious layering takes place in Emulsion in appearance.
Comparative example 2
Prescription is formed: with embodiment 1
Preparation method: take by weighing each component according to the prescription composition,, then cyclosporin A is dissolved in the mixture with Oleum Ricini, polyoxyethylene castor oil and glycerol mix homogeneously under 60 ℃ of conditions.Add an amount of purified water, emulsification pretreatment obtains colostrum, regulates viscosity to 2.6-3.5cp with the carbomer aqueous solution subsequently; The reuse sodium hydroxide solution is adjusted to pH6.2-8; Subsequently, add the recipe quantity benzalkonium chloride, mend to 1000ml with purified water, the product that makes is with the filtering with microporous membrane of 0.45 μ m.The mean diameter of prepared after measured microemulsion emulsion droplet is 150nm.
The Tween 80 that the emulsifying agent of embodiment 1 adopts polyoxyethylene castor oil to replace comparative example 1 to adopt adds and uses shearing-high pressure homogenize technology that resulting microemulsion formulation is not stratified, demonstrates good stable; Compare with comparative example 2, embodiment 1 substitutes common shearing technology with shearing-high pressure homogenize technology on preparation technology, and the mean diameter of resulting microemulsion formulation emulsion droplet is that 60nm significantly is lower than the 150nm Emulsion particle diameter that common shearing technology makes.
Embodiment 2
Prescription is formed: ciclosporin A 0.5g
Three sad caprin 6g
Polyoxyethylene castor oil 15g
Carbomer (Pemulen) 0.05g
Glycerol 26g
Sodium hydroxide is an amount of
Benzalkonium chloride 0.05g
Purified water is an amount of
Make 1000ml
Preparation method: take by weighing each component according to the prescription composition,, then cyclosporin A is dissolved in the mixture with three sad caprins, polyoxyethylene castor oil and glycerol mix homogeneously under 60 ℃ of conditions.Add an amount of purified water, emulsification pretreatment obtains colostrum, and then (pressure was about 100,000kPa), regulates viscosity to 2.6-3.5cp with the carbomer aqueous solution subsequently with high pressure homogenizer homogenizing 1 hour; The reuse sodium hydroxide solution is adjusted to pH6.2-8; Subsequently, add the recipe quantity benzalkonium chloride, mend to 1000ml with purified water, the product that makes is with the filtering with microporous membrane of 0.45 μ m.The mean diameter of prepared after measured microemulsion emulsion droplet is 52nm.
Embodiment 3
Prescription is formed: ciclosporin A 0.3g
Oleum Ricini 5g
Polyoxyethylene castor oil 10g
Carbomer (Pemulen) 0.05g
Glycerol 26g
Sodium hydroxide is an amount of
Benzalkonium chloride 0.05g
Purified water is an amount of
Make 1000ml
Preparation method: take by weighing each component according to the prescription composition,, then cyclosporin A is dissolved in the mixture with Oleum Ricini, polyoxyethylene castor oil and glycerol mix homogeneously under 60 ℃ of conditions.Add an amount of purified water, emulsification pretreatment obtains colostrum, and then (pressure was about 100,000kPa), regulates viscosity to 2.6-3.5cp with the carbomer aqueous solution subsequently with high pressure homogenizer homogenizing 6 hours; The reuse sodium hydroxide solution is adjusted to pH6.2-8; Subsequently, add the recipe quantity benzalkonium chloride, mend to 1000ml with purified water, the product that makes is with the filtering with microporous membrane of 0.45 μ m.The mean diameter of prepared after measured microemulsion emulsion droplet is 83nm.
Embodiment 4
Prescription is formed: ciclosporin A 1g
Oleum Ricini 12g
Polyoxyethylene castor oil 20g
Carbomer (Pemulen) 0.05g
Glycerol 26g
Sodium hydroxide is an amount of
Benzalkonium chloride 0.05g
Purified water is an amount of
Make 1000ml
Preparation method: take by weighing each component according to the prescription composition,, then cyclosporin A is dissolved in the mixture with Oleum Ricini, polyoxyethylene castor oil and glycerol mix homogeneously under 60 ℃ of conditions.Add an amount of purified water, emulsification pretreatment obtains colostrum, and then (pressure was about 150,000kPa), regulates viscosity to 2.6-3.5cp with the carbomer aqueous solution subsequently with high pressure homogenizer homogenizing 6 hours; The reuse sodium hydroxide solution is adjusted to pH6.2-8; Subsequently, add the recipe quantity benzalkonium chloride, mend to 1000ml with purified water, the product that makes is with the filtering with microporous membrane of 0.45 μ m.The mean diameter of prepared after measured microemulsion emulsion droplet is 90nm.
Embodiment 5
Prescription is formed: ciclosporin A 5g
Oleum Ricini 30g
Polyoxyethylene castor oil 50g
Carbomer (Pemulen) 0.05g
Glycerol 26g
Sodium hydroxide is an amount of
Benzalkonium chloride 0.05g
Purified water is an amount of
Make 1000ml
Preparation method: take by weighing each component according to the prescription composition,, then cyclosporin A is dissolved in the mixture with Oleum Ricini, polyoxyethylene castor oil and glycerol mix homogeneously under 60 ℃ of conditions.Add an amount of purified water, emulsification pretreatment obtains colostrum, and then (pressure was about 170,000kPa), regulates viscosity to 2.6-3.5cp with the carbomer aqueous solution subsequently with high pressure homogenizer homogenizing 8 hours; The reuse sodium hydroxide solution is adjusted to pH6.2-8; Subsequently, add the recipe quantity benzalkonium chloride, mend to 1000ml with purified water, the product that makes is with the filtering with microporous membrane of 0.45 μ m.The mean diameter of prepared after measured microemulsion emulsion droplet is 87nm.
Embodiment 6
Prescription is formed: ciclosporin A 0.1g
Oleum Ricini 1g
Polyoxyethylene castor oil 10g
Carbomer (Pemulen) 0.05g
Glycerol 26g
Sodium hydroxide is an amount of
Benzalkonium chloride 0.05g
Purified water is an amount of
Make 1000ml
Preparation method: take by weighing each component according to the prescription composition,, then cyclosporin A is dissolved in the mixture with Oleum Ricini, polyoxyethylene castor oil and glycerol mix homogeneously under 60 ℃ of conditions.Add an amount of purified water, emulsification pretreatment obtains colostrum, and then (pressure was about 140,000kPa), regulates viscosity to 2.6-3.5cp with the carbomer aqueous solution subsequently with high pressure homogenizer homogenizing 4 hours; The reuse sodium hydroxide solution is adjusted to pH6.2-8; Subsequently, add the recipe quantity benzalkonium chloride, mend to 1000ml with purified water, the product that makes is with the filtering with microporous membrane of 0.45 μ m.The mean diameter of prepared after measured microemulsion emulsion droplet is 46nm.
Embodiment 7
Prescription is formed: ciclosporin A 0.5g
Oleum Ricini 6g
Polyoxyethylene castor oil 10g
Carbomer (Pemulen) 0.05g
Glycerol 26g
Sodium hydroxide is an amount of
Benzalkonium chloride 0.05g
Purified water is an amount of
Make 1000ml
Preparation method: take by weighing each component according to the prescription composition,, then cyclosporin A is dissolved in the mixture with Oleum Ricini, polyoxyethylene castor oil and glycerol mix homogeneously under 60 ℃ of conditions.Add an amount of purified water, emulsification pretreatment obtains colostrum, and then (pressure was about 160,000kPa), regulates viscosity to 2.6-3.5cp with the carbomer aqueous solution subsequently with high pressure homogenizer homogenizing 6 hours; The reuse sodium hydroxide solution is adjusted to pH6.2-8; Subsequently, add the recipe quantity benzalkonium chloride, mend to 1000ml with purified water, the product that makes is with the filtering with microporous membrane of 0.45 μ m.The mean diameter of prepared after measured microemulsion emulsion droplet is 92nm.
Embodiment 8
Prescription is formed: ciclosporin A 0.1g
Oleum Ricini 12g
Polyoxyethylene castor oil 0.4g
Carbomer (Pemulen) 0.05g
Glycerol 26g
Sodium hydroxide is an amount of
Benzalkonium chloride 0.05g
Purified water is an amount of
Make 1000ml
Preparation method: take by weighing each component according to the prescription composition,, then cyclosporin A is dissolved in the mixture with Oleum Ricini, polyoxyethylene castor oil and glycerol mix homogeneously under 60 ℃ of conditions.Add an amount of purified water, emulsification pretreatment obtains colostrum, and then (pressure was about 180,000kPa), regulates viscosity to 2.6-3.5cp with the carbomer aqueous solution subsequently with high pressure homogenizer homogenizing 6 hours; The reuse sodium hydroxide solution is adjusted to pH6.2-8; Subsequently, add the recipe quantity benzalkonium chloride, mend to 1000ml with purified water, the product that makes is with the filtering with microporous membrane of 0.45 μ m.The mean diameter of prepared after measured microemulsion emulsion droplet is 86nm.
Embodiment 9
Prescription is formed: ciclosporin A 0.5g
Oleum Ricini 6g
Polyoxyethylene hydrogenated Oleum Ricini 15g
Carbomer (Pemulen) 0.05g
Glycerol 26g
Sodium hydroxide is an amount of
Benzalkonium chloride 0.05g
Purified water is an amount of
Make 1000ml
Preparation method: take by weighing each component according to the prescription composition,, then cyclosporin A is dissolved in the mixture with Oleum Ricini, polyoxyethylene castor oil and glycerol mix homogeneously under 60 ℃ of conditions.Add an amount of purified water, emulsification pretreatment obtains colostrum, and then (pressure was about 140,000kPa), regulates viscosity to 2.6-3.5cp with the carbomer aqueous solution subsequently with high pressure homogenizer homogenizing 4 hours; The reuse sodium hydroxide solution is adjusted to pH6.2-8; Subsequently, add the recipe quantity benzalkonium chloride, mend to 1000ml with purified water, the product that makes is with the filtering with microporous membrane of 0.45 μ m.The mean diameter of prepared after measured microemulsion emulsion droplet is 51nm.
Embodiment 10
Prescription is formed: ciclosporin A 0.5g
Oleum Ricini 6g
Polyoxyethylene castor oil 15g
Carbomer (1342) 0.05g
Glycerol 26g
Sodium hydroxide is an amount of
Benzalkonium chloride 0.05g
Purified water is an amount of
Make 1000ml
Preparation method: take by weighing each component according to the prescription composition,, then cyclosporin A is dissolved in the mixture with Oleum Ricini, polyoxyethylene castor oil and glycerol mix homogeneously under 60 ℃ of conditions.Add an amount of purified water, emulsification pretreatment obtains colostrum, and then (pressure was about 140,000kPa), regulates viscosity to 2.6-3.5cp with the carbomer aqueous solution subsequently with high pressure homogenizer homogenizing 4 hours; The reuse sodium hydroxide solution is adjusted to pH6.2-8; Subsequently, add the recipe quantity benzalkonium chloride, mend to 1000ml with purified water, the product that makes is with the filtering with microporous membrane of 0.45 μ m.The mean diameter of prepared after measured microemulsion emulsion droplet is 60nm.
Claims (7)
1, a kind of cyclosporin A for eyes microemulsion formulation, it consists of, in the content in the 1000ml microemulsion formulation:
Ciclosporin A 0.005g-5g
Oil phase 0.06g-30g
Emulsifying agent 0.3g-50g
Viscosifier 0.0g-1.0g
Glycerol 26g
Antibacterial 0.0g-0.5g
Sodium hydroxide is an amount of
Purified water is an amount of
Described emulsifying agent is polyoxyethylene castor oil or polyoxyethylene hydrogenated Oleum Ricini.
2, cyclosporin A for eyes microemulsion formulation according to claim 1 is characterized in that oil phase is Oleum Ricini or three sad caprins.
3, cyclosporin A for eyes microemulsion formulation according to claim 1, the weight ratio that it is characterized in that cyclosporin A and oil phase is 0.02～0.12.
4, cyclosporin A for eyes microemulsion formulation according to claim 1, the weight ratio that it is characterized in that oil phase and emulsifying agent is 0.5～2.
5, cyclosporin A for eyes microemulsion formulation according to claim 1 is characterized in that the emulsion droplet mean diameter less than 100nm, and 90% particle diameter accumulated value is smaller or equal to 200nm.
6, the described cyclosporin A for eyes of claim 1 preparation method of microemulsion formulation, it is characterized in that adopting shearing-high pressure homogenize technology, its operating procedure is with oil phase, emulsifying agent, glycerol mix homogeneously, then cyclosporin A is dissolved in the mixture, add an amount of purified water, emulsification pretreatment obtains colostrum, and then use the high pressure homogenizer homogenizing, regulate viscosity with tackifier water solution subsequently, the reuse sodium hydroxide solution is regulated pH, adds the recipe quantity antibacterial at last, mends to capacity with purified water, the product that makes is with the filtering with microporous membrane of 0.45 μ m, promptly.
7, the cyclosporin A for eyes according to claim 6 preparation method of microemulsion formulation, the pressure that it is characterized in that high pressure homogenize is more than or equal to 100, and 000kPa, homogenizing time are 1-20 hour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100246445A CN100478025C (en) | 2005-03-25 | 2005-03-25 | Cyclosporia A microemulsion for eye and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100246445A CN100478025C (en) | 2005-03-25 | 2005-03-25 | Cyclosporia A microemulsion for eye and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686533A CN1686533A (en) | 2005-10-26 |
| CN100478025C true CN100478025C (en) | 2009-04-15 |
Family
ID=35304575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100246445A Active CN100478025C (en) | 2005-03-25 | 2005-03-25 | Cyclosporia A microemulsion for eye and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100478025C (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10137083B2 (en) * | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
| US11311477B2 (en) * | 2006-03-07 | 2022-04-26 | Sgn Nanopharma Inc. | Ophthalmic preparations |
| CN101057966B (en) * | 2007-05-16 | 2011-04-13 | 中国科学院上海药物研究所 | Liposome nanometer carrier situ gel preparation used for eye epidermal growth factor |
| CN101897949B (en) * | 2010-02-24 | 2016-07-06 | 温士顿医药股份有限公司 | Low irritant transparent emulsion dosage form is for the medical composite for eye of eyes or the surface immunomodulating of around eyes related organization and antiinflammatory |
| CN101816642B (en) * | 2010-05-21 | 2011-06-29 | 鲍亚华 | Compound lidocaine emulsifiable paste and preparation method thereof |
| JP5805773B2 (en) * | 2010-10-12 | 2015-11-10 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | Cyclosporine analog |
| CN102525887A (en) * | 2012-01-16 | 2012-07-04 | 无锡信仁堂药物技术有限公司 | Cyclosporine-containing ophthalmic emulsion gel and preparation method thereof |
| KR101211902B1 (en) * | 2012-04-30 | 2012-12-13 | 주식회사 휴온스 | Non-irritating ophthalmic nano-emulsion composition comprising cyclosporin |
| KR102407735B1 (en) * | 2014-02-14 | 2022-06-10 | 징준 후앙 | Compositions of nanoemulsion delivery systems |
| CN105726479B (en) * | 2016-03-24 | 2018-06-22 | 北京茗泽中和药物研究有限公司 | cyclosporine ophthalmic emulsion |
| EP3266446B1 (en) * | 2016-07-07 | 2018-11-21 | Laboratorios SALVAT, S.A. | Ophthalmic composition comprising castor oil and medium chain triglyceride |
| CN107998399B (en) * | 2017-12-22 | 2021-01-12 | 北京诺康达医药科技股份有限公司 | Cyclosporine compound eye drops and preparation method thereof |
| CN108066745A (en) * | 2017-12-26 | 2018-05-25 | 兆科药业（广州）有限公司 | A kind for the treatment of process of Ciclosporin eye gel |
| CN110237233B (en) * | 2019-07-30 | 2021-01-15 | 沈阳兴齐眼药股份有限公司 | Ophthalmic pharmaceutical composition containing cyclosporine, preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1152876A (en) * | 1994-05-17 | 1997-06-25 | 阿勒根 | Laerimal gland specific emulsions for topical application to ocular tissue |
| CN1265920A (en) * | 1999-03-09 | 2000-09-13 | 杭州中美华东制药有限公司 | Medicinal composition containing cyclosporin |
| CN1280502A (en) * | 1997-12-05 | 2001-01-17 | 株式会社钟根堂 | Cyclosporin-containing microemulsion preconcentrate composition |
| CN1317342A (en) * | 2000-04-07 | 2001-10-17 | 梅迪多姆实验室股份有限公司 | Eye preparation |
-
2005
- 2005-03-25 CN CNB2005100246445A patent/CN100478025C/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1152876A (en) * | 1994-05-17 | 1997-06-25 | 阿勒根 | Laerimal gland specific emulsions for topical application to ocular tissue |
| CN1280502A (en) * | 1997-12-05 | 2001-01-17 | 株式会社钟根堂 | Cyclosporin-containing microemulsion preconcentrate composition |
| CN1265920A (en) * | 1999-03-09 | 2000-09-13 | 杭州中美华东制药有限公司 | Medicinal composition containing cyclosporin |
| CN1317342A (en) * | 2000-04-07 | 2001-10-17 | 梅迪多姆实验室股份有限公司 | Eye preparation |
Non-Patent Citations (1)
| Title |
|---|
| 环孢菌素A滴眼液的试剂与临床效果. 梁陈方.华夏医药，第1期. 1997 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1686533A (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100478025C (en) | Cyclosporia A microemulsion for eye and its preparation method | |
| CN103533962B (en) | A kind of ophthalmic composition | |
| Naguib et al. | Optimizing novel penetration enhancing hybridized vesicles for augmenting the in-vivo effect of an anti-glaucoma drug | |
| US11903986B2 (en) | Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye | |
| EP1754491B1 (en) | Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist | |
| US20230083458A1 (en) | Topical cyclosporine-containing formulations and uses thereof | |
| CA3072768C (en) | Pharmaceutical compositions for the treatment of ophthalmic conditions | |
| CN101244256A (en) | Micro/sub-micro emulsion in situ gel rubber preparation of cyclosporins A for eyes and preparation thereof | |
| CN107929235B (en) | Tacrolimus ophthalmic preparation and preparation method thereof | |
| CN108348468A (en) | Pegylated lipids nanoparticle with bioactive lipophilic compounds | |
| KR20100072333A (en) | Non-aqueous water-miscible materials as vehicles for drug delivery | |
| CN101653413B (en) | Tacrolimus ophthalmic emulsion and its preparation method | |
| CN106999543A (en) | ophthalmic composition comprising cyclosporin and trehalose | |
| CN101810563B (en) | Tacrolimus ophthalmic in-situ gel preparation and preparation method thereof | |
| CN105726479B (en) | cyclosporine ophthalmic emulsion | |
| CN100562340C (en) | A kind of micro-emulsion type artificial tear | |
| CN113577024B (en) | Ophthalmic composition, preparation method and application thereof | |
| CN111249442A (en) | Lipid nanocapsule eye drops and preparation method thereof | |
| CN101332180A (en) | Melbex eye drops and preparation method thereof | |
| US20210008029A1 (en) | Semisolid dosage forms for ophthalmic delivery of antioxidants | |
| CN101244035A (en) | Cyclosporins A emulsion preparations for eyes and preparation thereof | |
| US10702578B2 (en) | Ophthalmic compositions of cyclosporine | |
| CN107638433A (en) | A kind of triperygium wilfordii extractive and preparation method thereof and the application in eye drops is prepared | |
| Mundada | Update on Polymers for Ocular Drug Delivery | |
| CN101130058A (en) | Emulsion of cyclosporin A for eyes and method of producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHANGHAI PHARMACEUTICAL (GROUP) CO., LTD. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20100325 Address after: 201203 Shanghai city Zuchongzhi road Pudong Zhangjiang hi tech Park No. 555 Co-patentee after: Shanghai Pharmaceutical Stock Co., Ltd. Patentee after: Shanghai Institute of Materia Medica, Chinese Academy of Sciences Address before: 201203 Shanghai city Zuchongzhi road Pudong Zhangjiang hi tech Park No. 555 Co-patentee before: Shanghai Pharmaceutical (Group) Co., Ltd. Patentee before: Shanghai Institute of Materia Medica, Chinese Academy of Sciences |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: SHANGHAI XINYI JINZHU PHARMACEUTICAL CO., LTD. Assignor: Chinese Academy of Sciences, Shanghai Institute of Materia Medica|Shanghai pharmaceutical Limited by Share Ltd Contract record no.: 2010310000192 Denomination of invention: Cyclosporia A microemulsion for eye and its preparation method Granted publication date: 20090415 License type: Exclusive License Open date: 20051026 Record date: 20101019 |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 201203 Shanghai city Zuchongzhi road Pudong Zhangjiang hi tech Park No. 555 Co-patentee after: Shanghai Pharmaceuticals Holding Co., Ltd. Patentee after: Shanghai Institute of Materia Medica, Chinese Academy of Sciences Address before: 201203 Shanghai city Zuchongzhi road Pudong Zhangjiang hi tech Park No. 555 Co-patentee before: Shanghai Pharmaceutical Stock Co., Ltd. Patentee before: Shanghai Institute of Materia Medica, Chinese Academy of Sciences |